Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis

N Engl J Med. 2008 Jan 10;358(2):190-2. doi: 10.1056/NEJMe0707153.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angiomyolipoma / drug therapy
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Diseases / drug therapy
  • Lung Neoplasms / drug therapy*
  • Lymphangioleiomyomatosis / drug therapy*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / metabolism
  • Respiratory Function Tests
  • Sirolimus / therapeutic use*
  • TOR Serine-Threonine Kinases
  • Tuberous Sclerosis / drug therapy*
  • Tuberous Sclerosis Complex 1 Protein
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism

Substances

  • Immunosuppressive Agents
  • Protein Kinase Inhibitors
  • Tuberous Sclerosis Complex 1 Protein
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Suppressor Proteins
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus